CAMZYOS 15 mg, hard capsule 28 capsules
Active ingredients: Mavacamten
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule28 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CAMZYOS 15 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) PVC polychlortrifluoroéthylène aluminium de 28 gélule(s)
- Marketing authorisation holder
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 26 Feb 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
68577204CIP73027640CIP133400930276402Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MAVACAMTENgélule | 15 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.